Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1111/joim.13231

http://scihub22266oqcxt.onion/10.1111/joim.13231
suck pdf from google scholar
33511686!8013903!33511686
unlimited free pdf from europmc33511686    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid33511686      J+Intern+Med 2021 ; 289 (5): 738-746
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Tocilizumab in COVID-19 interstitial pneumonia #MMPMID33511686
  • Pomponio G; Ferrarini A; Bonifazi M; Moretti M; Salvi A; Giacometti A; Tavio M; Titolo G; Morbidoni L; Frausini G; Onesta M; Amico D; Rocchi MLB; Menzo S; Zuccatosta L; Mei F; Menditto V; Svegliati S; Donati A; D'Errico MM; Pavani M; Gabrielli A
  • J Intern Med 2021[May]; 289 (5): 738-746 PMID33511686show ga
  • BACKGROUND: Published reports on tocilizumab in COVID-19 pneumonitis show conflicting results due to weak designs or heterogeneity in critical methodological issues. METHODS: This open-label trial, structured according to Simon's optimal design, aims to identify factors predicting which patients could benefit from anti-IL6 strategies and to enhance the design of unequivocal and reliable future randomized trials. A total of 46 patients with COVID-19 pneumonia needing of oxygen therapy to maintain SO2 > 93% and with recent worsening of lung function received a single infusion of tocilizumab. Clinical and biological markers were measured to test their predictive values. Primary end point was early and sustained clinical response. RESULTS: Twenty-one patients fulfilled pre-defined response criteria. Lower levels of IL-6 at 24 h after tocilizumab infusion (P = 0.049) and higher baseline values of PaO2/FiO2 (P = 0.008) predicted a favourable response. CONCLUSIONS: Objective clinical response rate overcame the pre-defined threshold of 30%. Efficacy of tocilizumab to improve respiratory function in patients selected according to our inclusion criteria warrants investigations in randomized trials.
  • |*Antibodies, Monoclonal, Humanized/administration & dosage/pharmacokinetics[MESH]
  • |*COVID-19/diagnosis/epidemiology/physiopathology/therapy[MESH]
  • |*Interleukin-6/antagonists & inhibitors/blood[MESH]
  • |*Pneumonia, Viral/drug therapy/epidemiology/etiology[MESH]
  • |Aged[MESH]
  • |Biomarkers, Pharmacological/*analysis[MESH]
  • |Drug Monitoring/*methods[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Immunologic Factors/administration & dosage/pharmacokinetics[MESH]
  • |Infusions, Intravenous[MESH]
  • |Italy/epidemiology[MESH]
  • |Male[MESH]
  • |Oximetry/methods[MESH]
  • |Oxygen Inhalation Therapy/methods[MESH]
  • |Predictive Value of Tests[MESH]
  • |Respiratory Function Tests/methods[MESH]
  • |SARS-CoV-2/isolation & purification[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box